ATE464049T1 - Pharmazeutische kombinationen von hydrocodon und naltrexon - Google Patents

Pharmazeutische kombinationen von hydrocodon und naltrexon

Info

Publication number: ATE464049T1
Authority: AT; Austria
Prior art keywords: naltrexone; hydrocodone; pharmaceutical combinations; pharmaceutically acceptable; acceptable salt
Prior art date: 2003-09-25

Application number

AT04788669T

Other languages

English (en)

Inventor

Benjamin Oshlack

Curtis Wright

Chris Breder

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-25

Filing date

2004-09-09

Publication date

2010-04-15

2004-09-09 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE464049T1 publication Critical patent/ATE464049T1/de

Links

XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 title abstract 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 title abstract 2
229960000240 hydrocodone Drugs 0.000 title abstract 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 title abstract 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 2
229960003086 naltrexone Drugs 0.000 title abstract 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04788669T 2003-09-25 2004-09-09 Pharmazeutische kombinationen von hydrocodon und naltrexon ATE464049T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50622203P	2003-09-25	2003-09-25
PCT/US2004/029521 WO2005032555A2 (en)	2003-09-25	2004-09-09	Pharmaceutical combinations of hydrocodone and naltrexone

Publications (1)

Publication Number	Publication Date
ATE464049T1 true ATE464049T1 (de)	2010-04-15

Family

ID=34421533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04788669T ATE464049T1 (de)	2003-09-25	2004-09-09	Pharmazeutische kombinationen von hydrocodon und naltrexon

Country Status (13)

Country	Link
US (2)	US20060194826A1 (de)
JP (1)	JP4758897B2 (de)
AT (1)	ATE464049T1 (de)
AU (2)	AU2004277898B2 (de)
CA (1)	CA2539027C (de)
DE (1)	DE602004026604D1 (de)
DK (1)	DK1663229T3 (de)
ES (1)	ES2344350T3 (de)
HR (1)	HRP20100368T1 (de)
IL (1)	IL174537A (de)
MX (1)	MXPA06003392A (de)
PT (1)	PT1663229E (de)
WO (1)	WO2005032555A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU776666B2 (en)	2000-02-08	2004-09-16	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
US7943173B2 (en)	2001-07-18	2011-05-17	Purdue Pharma L.P.	Pharmaceutical combinations of oxycodone and naloxone
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
TWI347201B (en)	2003-04-21	2011-08-21	Euro Celtique Sa	Pharmaceutical products,uses thereof and methods for preparing the same
WO2004096201A1 (en)	2003-04-29	2004-11-11	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ES2761812T3 (es)	2005-11-22	2020-05-21	Nalpropion Pharmaceuticals Inc	Composición y métodos de aumento de la sensibilidad a la insulina
JP5478245B2 (ja) *	2006-06-05	2014-04-23	オレキシジェン・セラピューティクス・インコーポレーテッド	ナルトレキソンの徐放型配合物
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
KR20150082689A (ko)	2006-11-09	2015-07-15	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
EP2065038A1 (de) *	2007-11-30	2009-06-03	Pharnext	Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
WO2009076764A1 (en)	2007-12-17	2009-06-25	Labopharm Inc.	Misuse preventative, controlled release formulation
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
JP2011511782A (ja)	2008-02-12	2011-04-14	アボット・ラボラトリーズ	長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
BRPI0912014A2 (pt)	2008-05-09	2019-03-06	Grünenthal GmbH	processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
WO2009158114A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
JP5539991B2 (ja) *	2008-09-18	2014-07-02	パーデュー、ファーマ、リミテッド、パートナーシップ	ポリ（ε−カプロラクトン）を含む医薬剤形
CN102316857A (zh)	2008-12-16	2012-01-11	莱博法姆公司	防止误用的控释配方
WO2010141505A1 (en) *	2009-06-01	2010-12-09	Protect Pharmaceutical Corporation	Abuse-resistant delivery systems
EP2263665A1 (de)	2009-06-02	2010-12-22	Pharnext	Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en)	2009-06-02	2016-07-19	Pharnext	Compositions for treating CMT and related disorders
RU2015138422A (ru)	2009-07-22	2018-12-25	Грюненталь Гмбх	Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh)	2009-07-22	2012-07-11	格吕伦塔尔有限公司	热熔挤出的控制释放剂型
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
US9579285B2 (en)	2010-02-03	2017-02-28	Gruenenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of an extruder
US9277748B2 (en)	2010-03-12	2016-03-08	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Agonist/antagonist compositions and methods of use
NZ607392A (en)	2010-09-02	2015-03-27	Gruenenthal Chemie	Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo um polímero aniônico.
RS56527B1 (sr)	2011-07-29	2018-02-28	Gruenenthal Gmbh	Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es)	2011-07-29	2014-11-22	Gruenenthal Chemie	Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en)	2012-04-18	2018-11-19	Gruenenthal Gmbh	MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
HUE072188T2 (hu)	2012-06-06	2025-10-28	Nalpropion Pharmaceuticals Llc	Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
US20140179727A1 (en)	2012-12-14	2014-06-26	Trevi Therapeutics, Inc.	Methods for treating pruritus
US8637538B1 (en)	2012-12-14	2014-01-28	Trevi Therapeutics, Inc.	Methods for treatment of pruritis
US8987289B2 (en)	2012-12-14	2015-03-24	Trevi Therapeutics, Inc.	Methods for treating pruritus
AR096439A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
SMT201800534T1 (it)	2013-06-05	2019-01-11	Pharnext	Soluzioni orali stabili per principi attivi farmaceutici combinati
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014306759B2 (en)	2013-08-12	2018-04-26	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
AU2014356581C1 (en)	2013-11-26	2020-05-28	Grunenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
US10172797B2 (en)	2013-12-17	2019-01-08	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
MX2016014738A (es)	2014-05-12	2017-03-06	Gruenenthal Gmbh	Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es)	2014-05-26	2017-02-22	Gruenenthal Gmbh	Multiparticulas protegidas contra vertido de dosis etanolico.
EP3169315B1 (de)	2014-07-17	2020-06-24	Pharmaceutical Manufacturing Research Services, Inc.	Missbrauchssichere flüssigkeitsfülldosierform mit unmittelbarer freisetzung
US20160106737A1 (en)	2014-10-20	2016-04-21	Pharmaceutical Manufacturing Research Services, Inc.	Extended Release Abuse Deterrent Liquid Fill Dosage Form
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en)	2015-09-10	2018-02-22	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
US10383870B2 (en)	2016-06-10	2019-08-20	Pharnext	Early treatment of CMT disease
IL318587A (en)	2018-07-23	2025-03-01	Trevi Therapeutics Inc	Treatment of chronic cough, shortness of breath and wheezing
CA3166928A1 (en)	2020-01-10	2021-07-15	Trevi Therapeutics, Inc.	Methods of administering nalbuphine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
US4769372A (en)	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US5215758A (en)	1991-09-11	1993-06-01	Euroceltique, S.A.	Controlled release matrix suppository for pharmaceuticals
US5472943A (en)	1992-09-21	1995-12-05	Albert Einstein College Of Medicine Of Yeshiva University,	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
PT914097E (pt) *	1996-03-12	2002-06-28	Alza Corp	Composicao e forma de dosagem compreendendo antagonista de opioide
US6274591B1 (en) *	1997-11-03	2001-08-14	Joseph F. Foss	Use of methylnaltrexone and related compounds
US6375957B1 (en) *	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
DK1685839T3 (da) *	1997-12-22	2013-06-24	Euro Celtique Sa	Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh)	1997-12-22	2005-06-08	欧罗赛铁克股份有限公司	防止阿片样物质滥用的方法
AU776666B2 (en) *	2000-02-08	2004-09-16	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
US7943173B2 (en) *	2001-07-18	2011-05-17	Purdue Pharma L.P.	Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) *	2001-08-06	2003-08-21	Christopher Breder	Sequestered antagonist formulations
WO2003013525A1 (en) *	2001-08-06	2003-02-20	Euro-Celtique S.A.	Opioid agonist formulations with releasable and sequestered antagonist
US7332182B2 (en) *	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) *	2001-08-06	2010-11-30	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
ATE510534T1 (de) *	2002-03-14	2011-06-15	Euro Celtique Sa	Naltrexonhydrochlorid-zusammensetzungen
CA2478515C (en) *	2002-04-05	2010-09-28	Purdue Pharma	Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) *	2002-04-09	2003-10-09	Barry Sherman	Opioid antagonist compositions and dosage forms
WO2004071423A2 (en) *	2003-02-05	2004-08-26	Euro-Celtique S.A.	Methods of administering opioid antagonists and compositions thereof
TWI347201B (en) *	2003-04-21	2011-08-21	Euro Celtique Sa	Pharmaceutical products,uses thereof and methods for preparing the same
US20080020028A1 (en) *	2003-08-20	2008-01-24	Euro-Celtique S.A.	Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050245557A1 (en) *	2003-10-15	2005-11-03	Pain Therapeutics, Inc.	Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain

2004
- 2004-09-09 WO PCT/US2004/029521 patent/WO2005032555A2/en not_active Ceased
- 2004-09-09 JP JP2006528039A patent/JP4758897B2/ja not_active Expired - Fee Related
- 2004-09-09 AU AU2004277898A patent/AU2004277898B2/en not_active Ceased
- 2004-09-09 HR HR20100368T patent/HRP20100368T1/hr unknown
- 2004-09-09 DK DK04788669.2T patent/DK1663229T3/da active
- 2004-09-09 DE DE602004026604T patent/DE602004026604D1/de not_active Expired - Lifetime
- 2004-09-09 ES ES04788669T patent/ES2344350T3/es not_active Expired - Lifetime
- 2004-09-09 US US10/562,494 patent/US20060194826A1/en not_active Abandoned
- 2004-09-09 MX MXPA06003392A patent/MXPA06003392A/es active IP Right Grant
- 2004-09-09 AT AT04788669T patent/ATE464049T1/de active
- 2004-09-09 CA CA2539027A patent/CA2539027C/en not_active Expired - Fee Related
- 2004-09-09 PT PT04788669T patent/PT1663229E/pt unknown
2006
- 2006-03-23 IL IL174537A patent/IL174537A/en not_active IP Right Cessation
2009
- 2009-03-18 AU AU2009201097A patent/AU2009201097B2/en not_active Ceased
2014
- 2014-10-01 US US14/504,063 patent/US20150080423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2004277898B2 (en)	2009-04-02
MXPA06003392A (es)	2006-06-08
HRP20100368T1 (hr)	2010-08-31
JP2007506738A (ja)	2007-03-22
AU2004277898A1 (en)	2005-04-14
JP4758897B2 (ja)	2011-08-31
US20150080423A1 (en)	2015-03-19
IL174537A (en)	2012-01-31
AU2009201097A1 (en)	2009-04-09
WO2005032555A3 (en)	2005-05-12
WO2005032555A2 (en)	2005-04-14
CA2539027A1 (en)	2005-04-14
PT1663229E (pt)	2010-07-13
CA2539027C (en)	2010-02-23
DK1663229T3 (da)	2010-08-09
AU2009201097B2 (en)	2011-03-31
HK1091733A1 (en)	2007-01-26
ES2344350T3 (es)	2010-08-25
US20060194826A1 (en)	2006-08-31
AU2009201097A8 (en)	2009-04-23
IL174537A0 (en)	2006-08-01
DE602004026604D1 (de)	2010-05-27

Publication	Publication Date	Title
DE602004026604D1 (de)	2010-05-27	Pharmazeutische kombinationen von hydrocodon und naltrexon
ATE419039T1 (de)	2009-01-15	Pharmazeutische kombinationen von oxycodon und naloxon
EA200301165A1 (ru)	2004-06-24	Лекарственное средство на основе оксикодона
HUE040046T2 (hu)	2019-02-28	Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
DE60013630D1 (de)	2004-10-14	Arzneimittel zur behandlung von darmverstopfung und reizkolon
PT1585548T (pt)	2018-10-17	Composições e métodos de administração de agentes farmacológicos
WO2004005324A3 (en)	2004-03-25	Peptide composition for treatment of sexual dysfunction
CY1106697T1 (el)	2012-05-23	Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
BR0316948A (pt)	2005-10-18	Composto, formulação farmacêutica, e, uso de um composto
BRPI0410049A (pt)	2006-04-25	composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
TR200101719T2 (tr)	2002-08-21	Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
NO20062019L (no)	2006-07-06	P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme
AR034343A1 (es)	2004-02-18	Combinaciones farmaceuticas
EA200800880A1 (ru)	2009-02-27	Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
EA200700901A1 (ru)	2007-10-26	Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0102440D0 (sv)	2001-07-05	New compound
WO2005065648A3 (en)	2005-12-08	Novel drug compositions and dosage forms of topiramate
EP1849468A3 (de)	2007-11-07	Pharmazeutische Zusammensetzung enthaltend einen pde4 oder pde3/4 Inhibitor und eine Histaminrezeptorantagonisten
EP1784173A4 (de)	2009-07-01	Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat-derivaten
YU87501A (sh)	2004-05-12	Farmaceutski kompleksi
HUP0301906D0 (en)	2003-08-28	Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity
CY1110207T1 (el)	2015-01-14	Φαρμακευτικοι συνδυασμοι υδροκοδωνης και ναλτρεξονης
AU2003281257A8 (en)	2004-01-23	A novel use of rapamycin and structural analogues thereof
AR030660A1 (es)	2003-08-27	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
AU2002223703A1 (en)	2002-05-27	Prevention of development of dyskinesias